Core Insights - WuXi Biologics has been awarded "Biologics CDMO of the Year" for the ninth consecutive year at the 2026 CDMO Leadership Awards, highlighting its leadership in the CRDMO sector [1][2] - The company has achieved excellence in multiple categories, including "Best Scaling Support," "Best Analytical Services," "Best Overall Staff," and "Best Project Management" [1][2] Company Achievements - As of the end of 2025, WuXi Biologics has 945 integrated projects, with over 50% being complex modalities such as bi-/multi-specific antibodies and ADCs [2] - The timelines for WuXi Biologics from DNA to IND and from IND to BLA have been reduced to 6 months and 15 months, respectively, compared to industry averages of 10-12 months and 24-36 months [2] - The company has a 100% success rate in PPQ campaigns and has delivered over 350 large-scale batches (6,000 L – 16,000 L per batch) since 2017 [4] Manufacturing and Quality - WuXi Biologics operates 15 GMP-certified drug substance and drug product facilities globally, with a 100% success rate in GMP inspections and 136 facility license approvals [4] - The company has passed 46 regulatory inspections, including 22 by the FDA and EMA, and holds a 100% pass rate for FDA Pre-License Inspection [4] Technological Innovations - WuXi Biologics is advancing digital innovation in biologics research and manufacturing, achieving approximately 40% productivity gains through digital manufacturing solutions [5] - The launch of the digital twin platform PatroLab™ aims to enhance process performance and minimize risks in biologics manufacturing [6] Sustainability Commitment - The company emphasizes sustainability as a cornerstone of long-term growth, driving green technology innovations and promoting responsible practices across the value chain [9]

Core Insights - WuXi Biologics has achieved a historic record by winning six awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards, highlighting its leadership in bioprocessing, manufacturing, and digital innovation [1] Group 1: Awards and Recognition - The company won in categories such as Excellence in Bioprocessing Automation & Digitalization, Bioprocessing Facility of the Year, and Best Contract Development & Manufacturing Organization Award [1] - Dr. Sherry Gu was named CTO of the Year, and Dr. Jeremy Guo received the award for Head of Fill-Finish & Formulation of the Year, recognizing their contributions to biologics development and manufacturing [1] Group 2: Business Operations and Achievements - WuXi Biologics operates 945 integrated projects, with nearly 50% involving bi- and multi-specific antibodies and ADCs, making it one of the largest portfolios of complex biologics globally [1] - The company has achieved a 100% success rate in PPQ campaigns and delivered over 350 large-scale batches (6,000 L – 16,000 L per batch) since 2017 [1] - WuXi Biologics has passed 46 regulatory inspections, including 22 by the FDA and EMA, maintaining a 100% pass rate for FDA Pre-License Inspection [1] Group 3: Technological Innovations - The company launched WuXia™ TrueSite, achieving average mAb titers over 8.0 g/L, and advanced its high-dose delivery technologies, enabling protein concentrations of up to 230 mg/mL [1] - WuXi Biologics has integrated digital innovation across R&D and manufacturing, achieving approximately 40% productivity gains and a 20% improvement in efficiency through advanced planning systems [1] Group 4: Sustainability and ESG Commitment - WuXi Biologics emphasizes sustainability as a cornerstone of long-term growth, driving green technology innovations and achieving excellence in Environment, Social, and Governance (ESG) practices [2]

Core Insights - WuXi Biologics has achieved significant advancements in 2025 through its CRDMO model, enhancing its position as a preferred partner for biopharmaceutical innovators and multinational corporations [1][2] - The company reported a record high of 209 new integrated projects in 2025, bringing the total to 945, with approximately 50% of these projects originating from U.S. clients [2][8] - WuXi Biologics is focusing on complex modalities, particularly bispecific/multispecific antibodies and ADCs, which now account for nearly 50% of its total project pipeline [4][8] Project Development - The company added 23 new projects in 2025, including 6 Phase III and commercial projects, with a significant portion involving complex modalities [5] - Bispecific/multispecific antibodies and ADCs have seen a growth of approximately 30%, reaching 196 and 252 projects respectively, contributing nearly 20% of the company's revenue with over 120% year-over-year growth [4][8] Research and Innovation - WuXi Biologics' research services achieved record-breaking upfront payments and potential milestone values exceeding USD 4 billion in 2025, driven by T-cell engager deals [7] - The CD3 platform has been widely adopted in the industry, enhancing the efficacy-safety balance of bispecific antibodies [6][7] Manufacturing Capabilities - The total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025, with a strong focus on operational excellence and technology leadership [11][12] - WuXi Biologics completed 28 PPQs in 2025, maintaining a success rate of over 99% and delivering more than 350 large-scale batches since 2017 [12][13] Global Expansion - The company is increasing strategic investments in the U.S. and has commenced construction of new facilities in Singapore, positioning these sites as strategic hubs within its global network [14][15] - An MOU was signed with the Qatar Free Zones Authority to establish a strategic site in Qatar, expanding WuXi Biologics' global footprint [16] Digital Innovations - WuXi Biologics has integrated digital innovations across its operations, achieving approximately 40% productivity gains and a 20% improvement in efficiency through smart manufacturing solutions [18] - The launch of the digital twin platform PatroLab aims to enhance process performance and ensure high-quality biologics manufacturing [18] Sustainability Efforts - The company has made significant strides in sustainability, earning an MSCI AAA Rating and being recognized in various sustainability indices [19][23] - WuXi Biologics is committed to driving green technology innovations and fostering positive social and environmental impacts [23] Future Outlook - In 2026, WuXi Biologics aims to build on its strong momentum with accelerated growth driven by robust research and manufacturing capabilities [20]